A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 07 Jun 2017
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 30 May 2017 Planned End Date changed from 30 Dec 2018 to 30 Jan 2019.
- 30 May 2017 Planned primary completion date changed from 30 Dec 2018 to 30 Jan 2019.
- 19 Apr 2017 Planned End Date changed from 30 Nov 2018 to 30 Dec 2018.